tavaborole
Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed with a complete clearance rate of 6-7% and partial clearance rate of 23-24% in individuals whose “infection border does not reach the cuticle at the base of the large toenail.” Tavaborole was approved by the US FDA in July 2014. The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death,
Key facts
- Drug.image
- Tavaborole.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 150px
- Drug.image2
- Tavaborole ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 150px
- Drug.tradename
- Kerydin
- Drug.MedlinePlus
- a614049
- Drug.pregnancy_US
- N
- Drug.routes_of_administration
- Topical
- Drug.ATC_prefix
- D01
- Drug.ATC_suffix
- AE24
- Drug.legal_US
Article
9 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Pharmacokinetics
- Society and culture
- Economics
- See also
- References
- External links
Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed with a complete clearance rate of 6-7% and partial clearance rate of 23-24% in individuals whose “infection border does not reach the cuticle at the base of the large toenail.” Tavaborole was approved by the US FDA in July 2014. The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death, eliminating the fungal infection.
==Medical uses== Tavaborole is used in the treatment of onychomycosis. In clinical trials, tavaborole was more effective than the vehicle (ethyl acetate and propylene glycol) alone in curing onychomycosis. In two studies, fungal infection was eliminated using tavaborole in 6.5% of the cases vs. 0.5% using the vehicle alone, and 27.5% vs. 14.6% using the vehicle alone.